PMGC Holdings’ Northstrive Amends Development And License Agreement With Yuva Biosciences To Launch Three-Phase Program Advancing Four AI-Discovered Compounds And Updating AI Scope, IP, Field Of Use, And Financial Terms
Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup.The
Two companies working together on AI-discovered medicines just updated their deal to focus on their four best drug candidates and move them closer to testing in people. When companies expand deals based on good results, it often shows they believe in the science and want to invest more.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.